Timely immunisation of premature infants against rotavirus in the neonatal intensive care unit

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 99, Issue 6, 2014, Pages F445-F447

  Ladhani, Shamez N ^a,b   Ramsay, Mary E ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; RIX4414 VACCINE; ROTAVIRUS VACCINE;

HUMAN; IMMUNIZATION; INFANT, PREMATURE, DISEASES; NEWBORN; NEWBORN INTENSIVE CARE; PREMATURITY; PREVENTIVE HEALTH SERVICE; PROCEDURES; ROTAVIRUS INFECTIONS; UNITED KINGDOM;

GREAT BRITAIN; HUMANS; IMMUNIZATION PROGRAMS; IMMUNIZATION SCHEDULE; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; INTENSIVE CARE UNITS, NEONATAL; INTENSIVE CARE, NEONATAL; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINES, ATTENUATED;

EID: 84925030583     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/archdischild-2013-305744     Document Type: Article

References (30)

1. Harris JP, Jit M, Cooper D, et al. Evaluating rotavirus vaccination in England and Wales. Part I. Estimating the burden of disease. Vaccine 2007;25:3962-70.
2. Jit M, Edmunds WJ. Evaluating rotavirus vaccination in England and Wales. Part II. The potential cost-effectiveness of vaccination. Vaccine 2007;25:3971-9.
3. Van der Wielen M, Van DP. Pentavalent human-bovine (WC3) reassortant rotavirus vaccine in special populations: a review of data from the Rotavirus Efficacy and Safety Trial. Eur J Clin Microbiol Infect Dis 2008;27:495-501.
4. Newman RD, Grupp-Phelan J, Shay DK, et al. Perinatal risk factors for infant hospitalization with viral gastroenteritis. Pediatrics 1999;103:E3.
5. Sharma R, Hudak ML, Premachandra BR, et al. Clinical manifestations of rotavirus infection in the neonatal intensive care unit. Pediatr Infect Dis J 2002;21:1099-105.
6. Herruzo R, Omenaca F, Garcia S, et al. Identification of risk factors associated with nosocomial infection by rotavirus P4G2, in a neonatal unit of a tertiary-care hospital. Clin Microbiol Infect 2009;15:280-5.
7. Santosham M, Pathak A, Kottapalli S, et al. Neonatal rotavirus infection. Lancet 1982;1:1070-1.
8. Chandran A, Heinzen RR, Santosham M, et al. Nosocomial rotavirus infections: a systematic review. J Pediatr 2006;149:441-7.
9. Sharma R, Garrison RD, Tepas JJ III, et al. Rotavirus-associated necrotizing enterocolitis: an insight into a potentially preventable disease? J Pediatr Surg 2004;39:453-7.
10. Dearlove J, Latham P, Dearlove B, et al . Clinical range of neonatal rotavirus gastroenteritis. Br Med J (Clin Res Ed) 1983;286:1473-5.
11. Shim JO, Son DW, Shim SY, et al. Clinical characteristics and genotypes of rotaviruses in a neonatal intensive care unit. Pediatr Neonatol 2012;53:18-23.
12. Patel MM, Haber P, Baggs J, et al. Intussusception and rotavirus vaccination: a review of the available evidence. Expert Rev Vaccines 2009;8:1555-64.
13. Parashar UD, Orenstein WA. Editorial commentary: intussusception and rotavirus vaccination - balancing risk against benefit. Clin Infect Dis 2013;57:1435-7.
14. Anonymous. Chapter 27b: Rotavirus. In: Salisbury D, Ramay M, eds. Immunisation against infectious disease (the Green Book). London: Crown Copyright, 2013;329-42. https://www.gov.uk/government/uploads/system/uploads/attachment-data/file/254913/Green-Book-Chapter-27b-v2-0.pdf (accessed 01 Apr 2014).
15. Jaques S, Bhojnagarwala B, Kennea N, et al. Slow uptake of rotavirus vaccination in UK neonatal units. Arch Dis Child Fetal Neonatal Ed 2014;99:F252.
16. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006;354:11-22.
17. Omenaca F, Sarlangue J, Szenborn L, et al. Safety, reactogenicity and immunogenicity of the human rotavirus vaccine in preterm European Infants: a randomized phase IIIb study. Pediatr Infect Dis J 2012;31:487-93.
18. Vesikari T, Karvonen A, Prymula R, et al. Immunogenicity and safety of the human rotavirus vaccine Rotarix co-administered with routine infant vaccines following the vaccination schedules in Europe. Vaccine 2010;28:5272-9.
19. Vesikari T, Matson DO, Dennehy P, et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006;354:23-33.
20. Goveia MG, Rodriguez ZM, Dallas MJ, et al. Safety and efficacy of the pentavalent human-bovine (WC3) reassortant rotavirus vaccine in healthy premature infants. Pediatr Infect Dis J 2007;26:1099-104.
21. Fang AY, Tingay DG. Early observations in the use of oral rotavirus vaccination in infants with functional short gut syndrome. J Paediatr Child Health 2012;48:512-16.
22. Ramsay ME, Begg NT, Gandhi J, et al. Antibody response and viral excretion after live polio vaccine or a combined schedule of live and inactivated polio vaccines. Pediatr Infect Dis J 1994;13:1117-21.
23. European Medicinces Agency. Rotarix Summary of Product Characteristics. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000639/WC500054789.pdf (accessed 1 Apr 2014).
24. Smith CK, McNeal MM, Meyer NR, et al. Rotavirus shedding in premature infants following first immunization. Vaccine 2011;29:8141-6.
25. Anderson EJ. Rotavirus vaccines: viral shedding and risk of transmission. Lancet Infect Dis 2008;8:642-9.
26. Weintraub ES, Baggs J, Duffy J, et al. Risk of intussusception after monovalent rotavirus vaccination. N Engl J Med 2014;370:513-19.
27. Yih WK, Lieu TA, Kulldorff M, et al. Intussusception risk after rotavirus vaccination in U.S. infants. N Engl J Med 2014;370:503-12.
28. Bonhoeffer J, Siegrist CA, Heath PT. Immunisation of premature infants. Arch Dis Child 2006;91:929-35.
29. Stumpf KA, Thompson T, Sanchez PJ. Rotavirus vaccination of very low birth weight infants at discharge from the NICU. Pediatrics 2013;132:e662-5.
30. Crawford NW, Hunt RW. Rotavirus vaccine timeliness in special care nurseries. Arch Dis Child Fetal Neonatal Ed 2014;99:F251-2.